Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?
Open Access
- 21 February 2021
- Vol. 10 (2), 457
- https://doi.org/10.3390/cells10020457
Abstract
Heart failure (HF) represents the end-stage condition of several structural and functional cardiovascular diseases, characterized by reduced myocardial pump function and increased pressure load. The dysregulation of neurohormonal systems, especially the hyperactivity of the cardiac adrenergic nervous system (ANS), constitutes a hallmark of HF and exerts a pivotal role in its progression. Indeed, it negatively affects patients’ prognosis, being associated with high morbidity and mortality rates, with a tremendous burden on global healthcare systems. To date, all the techniques proposed to assess the cardiac sympathetic nervous system are burdened by intrinsic limits that hinder their implementation in clinical practice. Several biomarkers related to ANS activity, which may potentially support the clinical management of such a complex syndrome, are slow to be implemented in the routine practice for several limitations due to their assessment and clinical impact. Lymphocyte G-protein-coupled Receptor Kinase 2 (GRK2) levels reflect myocardial β-adrenergic receptor function in HF and have been shown to add independent prognostic information related to ANS overdrive. In the present manuscript, we provide an overview of the techniques currently available to evaluate cardiac ANS in HF and future perspectives in this field of relevant scientific and clinical interest.This publication has 105 references indexed in Scilit:
- Adrenergic Nervous System in Heart FailureCirculation Research, 2013
- The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: Implications for neural control of cardiac excitabilityJournal of Molecular and Cellular Cardiology, 2011
- Acute Changes in N-Terminal Pro-B-Type Natriuretic Peptide During Hospitalization and Risk of Readmission and Mortality in Patients With Heart FailureThe American Journal of Cardiology, 2011
- G Protein-Coupled Receptor Kinase 2 in Patients With Acute Myocardial InfarctionThe American Journal of Cardiology, 2011
- Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fractionAnnals of Medicine, 2010
- Catestatin: A multifunctional peptide from chromogranin ARegulatory Peptides, 2010
- Dynamic Changes in Lymphocyte GRK2 Levels in Cardiac Transplant Patients: A Biomarker for Left Ventricular FunctionClinical and Translational Science, 2010
- Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart FailureCirculation, 2007
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJCI Insight, 2007
- Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart FailureThe New England Journal of Medicine, 1984